丹参制剂与心脑血管、抗癌化学药联合用药的药动学研究进展

查阅近十年相关文献，对丹参制剂与心脑血管、抗肿瘤化学药联合用药的药动学研究进行整理分析和归纳总结。结果显示，丹参制剂对一些心脑血管和抗癌化学药的大鼠体内药动学参数会产生显著影响，如显著提高降脂药阿伐他丁、匹伐他丁和瑞伐他丁的血药浓度；显著提高抗癌药甲氨蝶呤和阿霉素的血药浓度或延长体内消除；分析整理文献，建议丹参制剂与抗血小板聚集药联合用药要慎重。联合用药时应关注其安全性、适当调整剂量，今后需要进一步开展基于代谢酶和转运体介导的药动学机制研究。

Study progresses of pharmacokinetics of Danshen preparations combined with cardio cerebrovascular and anticancer chemical drugs

Relevant literatures in recent 10 years were retrieved to analyze and summarize studies on pharmacokinetics of Danshen preparations combined with cardio cerebrovascular and anticancer chemical drugs. Danshen preparations could produce obvious influence on pharmacodynamics of cardio cerebrovascular and anticancer chemical drugs in rats, significantly increase blood concentrations of cardio cerebrovascular drugs including atorvastatin, pitavastatin, rosuvastatin, anticancer drugs including methotrexate and adriamycin, or prolong internal elimination. The summarized literatures suggested that, it should be cautious when Danshen preparations were combined with antiplatelet agents. Attentions should be paid on medication safety and dose adjustment during combination. And further studies are needed to investigate pharmacodynamic mechanism to mediate metabolic enzymes and transporters.